Evidence map›Paper›PMID 40909279›Full record

ArticleFrontiers in immunology2025

SLAMF7 (CD319) enhances cytotoxic T-cell differentiation and sensitizes CD8

Jan-Erik Sander, Irina Han, Lisette Fickenscher, Jörg-Peter Schmidt, Hartmut Kroll, Tereza Vosikova, Martin Durisin, Holger Lingel, Monika C Brunner-Weinzierl

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Jan-Erik SanderDepartment of Experimental Pediatrics, University Hospital, Otto-von-Guericke-University, Magdeburg, Germany.
Irina HanDepartment of Experimental Pediatrics, University Hospital, Otto-von-Guericke-University, Magdeburg, Germany.
Lisette FickenscherDepartment of Experimental Pediatrics, University Hospital, Otto-von-Guericke-University, Magdeburg, Germany.
Jörg-Peter SchmidtInstitute for Transfusion Medicine Dessau, Red Cross Blood Transfusion Service NSTOB, Dessau, Germany.
Hartmut KrollInstitute for Transfusion Medicine Dessau, Red Cross Blood Transfusion Service NSTOB, Dessau, Germany.
Tereza VosikovaDepartment of Otorhinolaryngology, Head and Neck Surgery, University Hospital, Otto-von-Guericke-University, Magdeburg, Germany.
Martin DurisinDepartment of Otorhinolaryngology, Head and Neck Surgery, University Hospital, Otto-von-Guericke-University, Magdeburg, Germany.
Holger LingelDepartment of Experimental Pediatrics, University Hospital, Otto-von-Guericke-University, Magdeburg, Germany.
Monika C Brunner-WeinzierlDepartment of Experimental Pediatrics, University Hospital, Otto-von-Guericke-University, Magdeburg, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tumors frequently evade immune destruction by impairing cytotoxic CD8

Indexed as

CD8-Positive T-LymphocytesCell DifferentiationHead and Neck NeoplasmsImmune Checkpoint InhibitorsSignaling Lymphocytic Activation Molecule FamilySquamous Cell Carcinoma of Head and NeckT-Lymphocytes, CytotoxicCD28 AntigensHumansLymphocyte ActivationCD28 AntigensImmune Checkpoint InhibitorsSignaling Lymphocytic Activation Molecule FamilySLAMF7 protein, humancancercostimulationcytotoxicityhead and neck squamous cell carcinoma (HNSCC)immunotherapySLAMF familyT-cell differentiationtumor rejection

Identifiers

PMID40909279
PMCPMC12405405

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.